| Reason for the Action |
Werfen Australia has identified two problems affecting the Aptiva CTD Essential Reagent
1. The Instructions for Use for Aptiva CTD Essential Reagent (Part No. 723100), document 723100.DI_EN.C, Revision 09, released in July 2026, state that the assay is intended for use in adult and paediatric populations. Available performance evaluation data are insufficient to establish performance in paediatric populations. The IFU has been revised to remove the paediatric population claim and specify use in adult populations.
2. The shelf life of Aptiva CTD Essential Reagent has been reduced from 24 months to 12 months.
Use of the product beyond its supported shelf life, or in paediatric patients, may produce an incorrect test result.
To date, no complaints or adverse events related to these problems have been reported in Australia or worldwide. |